SLC5A2 and diabetes mellitus: Therefore, it is possible that SGLT2 inhibitors also regulate sphingolipid metabolism in the plasma and organs of diseases other than diabetes, e.g., Ang II contributes via multiple mechanisms in the development and maintenance of various pathologies including the metabolic, renal, cardiac, and hepatic [32,33].